The contrast is striking because cortical thinning is generally associated with normal aging and, when accelerated in specific areas, with neurodegenerative disease. The cerebral cortex is the brain’s folded outer layer, containing networks involved in memory, language, attention, decision-making and sensory processing. In Alzheimer’s disease, damage often emerges in a characteristic sequence that includes the entorhinal cortex, which serves as an important gateway for memory networks, followed by temporal and other cortical regions. In the new study, researchers focused on a composite measure encompassing the entorhinal, fusiform, inferior temporal and middle temporal cortices—areas known to be especially susceptible to Alzheimer’s-related changes.

The study combined data from two independent research groups that differed substantially in both age and sex. One group included 387 men from the Vietnam Era Twin Study of Aging, with an average age of about 62 years. The other consisted of 1,097 women participating in the Women’s Health Initiative Memory Study, whose average age was approximately 78. Using participants’ residential histories, the researchers estimated exposure to outdoor PM2.5 and NO2 during the three years preceding each person’s MRI scan. PM2.5 refers to airborne particles no larger than 2.5 micrometers in diameter—roughly one-thirtieth the width of a human hair. Because of their small size, these particles can penetrate deep into the lungs and may trigger systemic biological effects. Nitrogen dioxide is a reactive gas produced largely by fuel combustion, particularly from traffic and other urban sources.

Among the older women, higher exposure to both pollutants was associated with a thinner cortex across the Alzheimer’s-vulnerable regions. The researchers calculated that each additional microgram per cubic meter of PM2.5 exposure corresponded to an estimated cortical-thickness difference comparable to approximately 13 months of aging. For NO2, each additional part per billion was associated with a difference comparable to roughly three months of aging. These comparisons do not mean that pollution literally adds a fixed number of months to a person’s biological age, nor do they establish that exposure caused the tissue changes. Instead, they provide a way to express the size of the statistical association relative to typical age-related differences in cortical thickness.

The pollution signal was not limited to the four Alzheimer’s-related regions. In the older women, higher PM2.5 exposure was associated with a thinner cortex in 23 of the 34 brain regions examined, spanning the frontal, parietal, temporal and occipital lobes. Such a widespread pattern suggests that the effects of air pollution, if confirmed, may involve broad brain systems rather than a single memory circuit. Potential pathways include inflammation, oxidative stress, impaired blood-vessel function and disruption of the blood-brain barrier, a selective cellular interface that helps regulate which substances enter nervous tissue. Fine particles may also influence the brain indirectly through the lungs and bloodstream, although the present study did not measure the biological mechanisms responsible for the observed associations.

The younger men displayed a very different pattern. In this group, greater exposure to PM2.5 and NO2 was associated with a thicker cortex in the Alzheimer’s-vulnerable regions. While a thicker cortex is often interpreted as a sign of healthier brain tissue, that assumption is not always reliable. Some research suggests that cortical thickening can occur during early phases of certain disease processes, potentially reflecting inflammation, fluid-related swelling, enlargement of glial or neural cells, or other compensatory responses. Early pathological changes related to amyloid accumulation may also alter brain structure before later neurodegeneration produces measurable thinning. However, the study did not measure amyloid, tau, inflammation or other biomarkers, so none of these explanations can be confirmed.

An age-related analysis offered a possible clue to the divergent findings. Among the men, the positive association between PM2.5 exposure and cortical thickness gradually weakened between approximately ages 55 and 64 and became negative after around age 65. The later negative association was not statistically significant, meaning the evidence was insufficient to rule out the possibility that it resulted from chance. Even so, the trajectory raises the possibility that the brain’s structural response to pollution may change over the course of aging. A temporary thickening phase could represent an early biological reaction, followed by thinning as damage accumulates. This interpretation remains a hypothesis rather than a demonstrated sequence, because the participants were assessed at a single point in time rather than repeatedly over many years.

The researchers emphasize that the study cannot determine whether age, sex or other differences between the two groups explain the contrasting results. The participants came from separate cohorts with different demographic, health and life-history characteristics, and the analysis was observational. Residential pollution estimates also represent modeled exposure rather than direct personal measurements and may not capture time spent indoors, occupational exposure, indoor pollution, individual activity patterns or differences in pollutant composition. In addition, brain structure can be influenced by education, cardiovascular health, genetics, socioeconomic conditions, smoking, physical activity and many other factors. Statistical associations in MRI data therefore cannot be interpreted as proof that air pollution directly caused cortical injury or that the participants will develop Alzheimer’s disease.

Even with these limitations, the findings add to a growing body of research linking environmental exposures with brain aging and dementia-related biology. Air pollution is widespread, persistent and potentially modifiable through changes in transportation, energy production, urban planning and public-health policy. The study’s senior investigators argue that advanced neuroimaging can help identify possible effects of pollution years before dementia symptoms become visible. The next stage of research will require longitudinal studies that follow men and women from the same cohorts over time, repeatedly measure pollution exposure and brain structure, and include biomarkers for amyloid, tau, inflammation and vascular injury. Researchers will also need to track cognitive performance to determine whether pollution-related cortical changes predict memory decline or elevated Alzheimer’s risk. Until those studies are completed, the central message is one of caution: air pollution may leave a measurable imprint on the aging brain, but that imprint may not be uniform—and a thicker cortex at one stage of life may not necessarily signal better brain health.

Subject of Research: People

News Publication Date: 14-Jul-2026

Web References: https://ini.usc.edu/ ; https://keck.usc.edu/faculty-search/lauren-salminen/ ; https://doi.org/10.1016/j.neuro.2026.103495

References: NeuroToxicology, DOI: 10.1016/j.neuro.2026.103495

Image Credits: Stevens INI

Keywords: Air pollution, PM2.5, nitrogen dioxide, NO2, Alzheimer’s disease, cortical thickness, brain aging, neuroscience, environmental health, neurodegeneration

REM sleep behavior disorder is characterized by the loss of normal muscle atonia during rapid eye movement sleep, leading to enactment of vivid, often violent dreams. It represents a critical clinical marker for neurodegenerative diseases linked to α-synuclein protein aggregation in the central nervous system. However, the presence of α-synuclein in the cerebrospinal fluid, detectable through advanced biomarker assays, has established itself as a crucial element for confirming the neurodegenerative trajectory of these disorders. The current research breaks new ground by identifying a distinct subgroup of iRBD patients who, paradoxically, do not demonstrate this pathological hallmark in their CSF analyses.

The clinical implications of this discovery are profound. Traditionally, a positive α-synuclein biomarker in CSF has served as an early diagnostic tool predicting neurodegeneration, offering a window into disease progression before overt motor symptoms manifest. Yet, this newly characterized cohort of α-synuclein-negative individuals compels neurologists to reconsider diagnostic criteria and predictive models. It suggests that the pathological landscape of iRBD—and possibly synucleinopathies—is more heterogeneous than previously appreciated.

Delving into the molecular intricacies, the researchers utilized highly sensitive seeding aggregation assays (SAAs) and immunoassays to detect phosphorylated α-synuclein, the pathogenic form implicated in Lewy body formation. This approach allowed the team to distinguish between true α-synuclein negative status and potential assay limitations. Their findings indicate that the absence of CSF α-synuclein in certain iRBD patients is not an artifact but a genuine biological phenomenon, potentially pointing to alternative neurodegenerative pathways or protective mechanisms mitigating α-synuclein accumulation.

Neuroimaging data collected alongside CSF analyses further corroborated the biological divergence in this patient subgroup. Positron emission tomography (PET) and magnetic resonance imaging (MRI) revealed differential patterns of brain metabolism and structural integrity, suggesting that neurodegeneration in α-synuclein-negative iRBD might follow a distinct trajectory, potentially sparing some regions typically vulnerable in classical synucleinopathies. Such imaging insights offer tantalizing clues about the spatial and temporal dynamics of disease evolution in these patients.

From a clinical standpoint, symptoms and disease progression rates among the α-synuclein-negative iRBD group showed unexpected variance compared to their α-synuclein-positive counterparts. Cognitive assessments and motor function evaluations suggested a slower progression in some patients, raising important questions about the prognostic significance of α-synuclein negativity. This observation could inform when and how to target therapeutic interventions and streamline patient stratification for clinical trials examining neuroprotective strategies.

At the cellular level, the absence of CSF α-synuclein in these patients raises provocative hypotheses about the underlying neuropathology. It posits that other pathogenic proteins, such as tau or TDP-43, might be implicated, or that compensatory synaptic and immune responses curtail α-synuclein spread. Understanding these mechanisms is crucial for designing novel therapeutic targets beyond α-synuclein aggregation, potentially opening new avenues in treating or even preventing neurodegenerative conditions.

The study further explored potential genetic factors contributing to this phenotype. Whole-genome sequencing and targeted genetic analyses hinted at unique variants and epigenetic factors in the α-synuclein-negative group, which may modulate protein expression, aggregation propensity, or clearance mechanisms. Such genetic footprints could unlock personalized therapeutic approaches and enhance risk stratification, underscoring the importance of integrating molecular genetics with clinical neurology.

Importantly, the discovery has significant ramifications for biomarker development and clinical trial design. Current trials relying on CSF α-synuclein positivity for patient inclusion risk excluding a subset of iRBD patients who may otherwise benefit from intervention. This necessitates a reevaluation of biomarker panels to incorporate a broader spectrum of molecular indicators, ensuring inclusivity and improving trial efficacy.

Scientists also emphasize the need for longitudinal studies to elucidate the long-term outcomes of α-synuclein-negative iRBD patients. Whether these individuals eventually develop classic synucleinopathy or remain stable remains an open question critical to patient counseling and management. Continuous monitoring using multimodal biomarkers—encompassing fluid, imaging, and clinical markers—will be essential for mapping disease trajectories and refining predictive models.

The implications of this research stretch beyond Parkinson’s disease and associated disorders. They challenge the prevailing dogma in neurobiology about proteinopathy-centric paradigms and advocate a more nuanced understanding of neurodegeneration. By revealing unexpected biological diversity within clinically defined syndromes, the study promotes a precision medicine framework grounded in molecular pathology and individualized patient profiles.

Methodologically, this investigation exemplifies cutting-edge translational research, integrating biochemical, genetic, neuroimaging, and clinical data from large, multicenter cohorts. Advanced computational analytics allowed the cross-validation of findings and ensured robustness against confounding variables, setting a benchmark for future biomarker-driven neuroscience studies.

Moreover, the study has garnered significant interest due to its potential impact on public health strategies addressing neurodegenerative diseases. Early detection and intervention remain the cornerstone of managing these otherwise incurable conditions. Identifying unique subgroups like the α-synuclein-negative iRBD patients widens the scope for tailored screening programs and preventive measures, ultimately aiming to reduce disease burden at the population level.

Experts agree that translating these insights into clinical practice will require concerted efforts across disciplines, including neurology, molecular biology, genetics, and bioinformatics. Collaborative networks and data sharing will expedite validation and facilitate the development of next-generation diagnostic and therapeutic tools, harnessing the promise illuminated by this pivotal study.

In summary, the characterization of isolated REM sleep behavior disorder patients with cerebrospinal fluid α-synuclein negativity heralds a paradigm shift in the field of neurodegeneration research. It highlights the heterogeneity of prodromal synucleinopathies and uncovers novel molecular signatures that may underpin divergent disease pathways. This landmark study demands a reevaluation of current diagnostic standards, offers new therapeutic targets, and promises to refine prognostic frameworks, ultimately advancing personalized medicine for neurodegenerative disorders.

Subject of Research: Characterization of isolated REM sleep behavior disorder patients with cerebrospinal fluid α-synuclein negativity.

Article Title: Characterization of patients with isolated REM sleep behavior disorder and cerebrospinal fluid α-synuclein negativity.

Article References:
Farfán, F., Mamman, A., Maya, G. et al. Characterization of patients with isolated REM sleep behavior disorder and cerebrospinal fluid α-synuclein negativity. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01410-y

Image Credits: AI Generated

Alzheimer’s disease (AD) has long been associated with the APOE gene, which exists in three major isoforms: APOE2, APOE3, and APOE4. Among these, APOE4 is recognized as a major genetic risk factor for late-onset AD, whereas APOE2 appears to confer protective effects. Previous research has firmly established that APOE genotype influences amyloid plaque deposition, a pathological hallmark of AD. However, whether switching from APOE4 to APOE2 within specific brain cell types late in disease progression could ameliorate pathology and cognitive deficits remained largely unexplored until now.

The research team employed a sophisticated genetic engineering approach to specifically replace APOE4 with APOE2 exclusively in astrocytes—the star-shaped glial cells known to regulate neuronal support and amyloid metabolism. By crossing APOE4s2^A mice with the 5xFAD transgenic mouse model, which rapidly develops AD-related amyloid pathology, and administering tamoxifen to induce the allelic switch at 6 months of age, the scientists created a system to investigate late-stage therapeutic gene replacement.

Two months after inducing the APOE4 to APOE2 allelic switch within astrocytes, mice underwent a battery of cognitive tests, including associative fear conditioning and the Morris water maze. The results revealed a striking improvement in associative learning and memory, particularly in female mice, while spatial memory as assessed by the water maze test showed no significant changes. This dissociation suggests that astrocytic APOE genotype influences certain cognitive domains more robustly than others.

Critically, histopathological analysis of the brain tissues demonstrated that the astrocyte-specific APOE switch substantially lowered amyloid plaque load compared to controls. Quantitative immunohistochemistry revealed a pronounced decrease in total amyloid-positive areas in the brain, indicating that even after pathology has been established, astrocytic APOE2 expression can slow or delay further amyloid accumulation. Remarkably, this effect was regionally widespread, with significant plaque reductions observed in the hippocampus, olfactory area, and thalamus—regions heavily implicated in cognitive functions disrupted in AD.

To rigorously quantify amyloid pathology, enzyme-linked immunosorbent assays (ELISA) measured soluble and insoluble forms of Aβ40 and Aβ42 peptides from whole brain homogenates. The introduction of APOE2 specifically in astrocytes resulted in significant reductions in both soluble and insoluble amyloid beta isoforms, underscoring a comprehensive attenuation of amyloid pathology at a molecular level. These findings align well with the known roles of astrocytes in amyloid clearance and homeostasis.

Interestingly, the study found minimal sex differences in pathological outcomes, except for slightly higher baseline amyloid burdens in female control mice. The reduction in plaque load post-switch was consistent across sexes, implying that astrocyte-targeted APOE alterations have robust therapeutic potential irrespective of gender. While some subtle sex-dependent effects were noted in synaptic markers distal to plaques, overall synaptic integrity was preserved following APOE switching.

In considering other cerebrovascular impacts, the team evaluated cerebral amyloid angiopathy (CAA), another APOE4-associated pathology characterized by amyloid deposits in brain vasculature. Surprisingly, astrocyte-specific conversion to APOE2 did not significantly alter CAA burden. This suggests that while parenchymal amyloid plaques are strongly modulated by astrocytic APOE genotype, vascular amyloid deposition may be regulated by additional or alternative mechanisms, potentially involving other cell types or systemic factors.

Additionally, the expression of ZO1, a tight junction protein critical for maintaining blood-brain barrier integrity, remained unchanged after the allelic switch, indicating that the intervention did not compromise vascular barrier properties. This highlights the specificity and safety profile of the astrocytic gene conversion strategy, which does not appear to induce detrimental vascular side effects.

Collectively, the findings of this study offer compelling evidence that a targeted, late-stage allelic switch from APOE4 to APOE2 in astrocytes can alleviate key pathological and cognitive features of AD in a mouse model. By effectively reducing amyloid plaque burden and improving associative memory, this approach stands out as a promising avenue for therapeutic development that might be translatable into human interventions.

Traditionally, Parkinson’s disease diagnosis hinges heavily on motor symptom assessment alongside neuroimaging techniques, yet these often detect disease at a stage when substantial neurodegeneration has already occurred. Similarly, iRBD, characterized by the loss of normal muscle atonia during rapid eye movement sleep causing dream enactment behaviors, is widely recognized as a prodromal marker for synucleinopathies including PD, but suffers from diagnostic ambiguity and prognostic uncertainty. The sebum volatilome profiling offers a promising biomolecular fingerprint that captures early disease signatures with specificity and sensitivity, ushering in a new era of precision medicine in neurodegeneration.

The study, spearheaded by Walton-Doyle and colleagues, utilized advanced mass spectrometry coupled with sophisticated machine learning algorithms to analyze and classify sebum-derived VOC signatures from patient cohorts diagnosed with PD and iRBD. Sebum, an oily secretion primarily from sebaceous glands, has emerged as a surprising but remarkably informative biofluid given its accessibility and biochemical complexity. Its volatile compounds reflect metabolic alterations at the cellular level pertinent to neurodegenerative pathology, including oxidative stress, lipid peroxidation, and mitochondrial dysfunction — all hallmarks of PD progression.

Crucially, the researchers identified distinct clusters of VOCs that reliably segregated PD from iRBD participants, not only confirming the potential of the sebum volatilome as a diagnostic biosensor but also illuminating biochemical pathways implicated in the transition from isolated sleep disorder to manifest neurodegeneration. These biomarkers encompassed molecules related to branched-chain amino acid metabolism, altered fatty acid derivatives, and oxidative byproducts, which converge on neuronal integrity and inflammation. This molecular delineation provides compelling evidence that peripheral metabolic changes are tightly coupled with central nervous system degeneration.

Of particular interest was the temporal aspect of disease evolution uncovered through longitudinal analysis of the volatilome profiles. The study demonstrated that specific VOC signatures intensify and shift with disease progression, offering a quantifiable metric for monitoring neurodegenerative trajectory. This capability suggests future applications not only in early detection but also in therapeutic response evaluation and prognostic modeling. Such dynamic biomarker platforms are urgently needed to facilitate clinical trials and personalized medicine for PD, a disease notoriously heterogeneous in clinical course and treatment responsiveness.

The methodology employed underscores the integration of cutting-edge analytical chemistry with computational expertise. High-resolution mass spectrometry permitted the meticulous identification and quantification of hundreds of VOCs with unprecedented fidelity. Concurrently, machine learning classifiers such as random forests and support vector machines distilled these complex datasets into robust predictive models, capable of classifying disease status with high accuracy. This interdisciplinary approach exemplifies the power of combining omics technologies with artificial intelligence to tackle intricate biomedical challenges.

Beyond its immediate clinical implications, this research also contributes substantially to the understanding of PD pathophysiology. The observed alterations in lipid metabolism and oxidative stress-related VOCs corroborate existing hypotheses about mitochondrial impairment and neuroinflammation in PD etiology. Sebum VOCs thus not only serve as passive markers but actively reflect ongoing pathogenic processes, reinforcing the skin and its secretions as peripheral mirrors of central nervous system health. This paradigm shift opens novel investigative avenues, including exploration of skin-targeted interventions or monitoring systemic metabolic shifts as part of comprehensive PD care.

Moreover, the non-invasive nature of sebum sampling addresses a critical barrier in neurodegenerative disease research and diagnostics. Conventional methods such as cerebrospinal fluid analysis or neuroimaging are invasive, expensive, or logistically challenging. In contrast, sebum sampling is simple, painless, and readily adaptable to routine clinical settings or even home-based testing. Such practicality paves the way for large-scale screening programs and continuous monitoring, which are essential for early intervention especially in at-risk populations like those with iRBD.

However, the researchers are careful to note that despite promising results, further validation in larger, more diverse cohorts is required to solidify clinical utility and generalizability. Inclusion of longitudinal cohorts, varying disease severities, and controls with other neurodegenerative disorders will be vital to refine the biomarker panels and rule out confounding factors. Additionally, standardization of sampling protocols and analytical pipelines will be necessary to translate these findings into robust clinical assays.

The open questions arising from this study also highlight areas for future research. How do these sebum VOC signatures interact with genetic risk factors such as SNCA and LRRK2 mutations? What is the precise mechanistic link between peripheral lipid metabolism changes and central neurodegenerative cascades? Can interventions aimed at modifying these metabolic pathways alter disease course? Addressing these will deepen mechanistic insights and expand therapeutic horizons, potentially transforming PD from a relentlessly progressive condition to a manageable chronic disease.

Importantly, the socio-economic implications of such an easy-to-administer, early diagnostic tool are profound. Parkinson’s disease affects millions globally and imposes enormous healthcare costs and caregiver burdens. Early, accurate classification of PD versus iRBD and other mimickers can prevent misdiagnosis, optimize resource allocation, and improve patient quality of life by enabling timely therapeutic measures. Public health strategies incorporating volatilome analysis could significantly reduce disease impact at population levels.

Furthermore, this study exemplifies the potential of volatilomics, the study of volatile metabolites, as a burgeoning field within biomarker discovery. Beyond neurodegenerative diseases, volatilome analysis holds promise in oncology, infectious diseases, and metabolic disorders. The skin volatilome, in particular, offers a rich, underexplored source of biological information accessible through simple sampling techniques such as skin swabs or patches. Technologies harnessed here could thus spur a wave of innovations across medical diagnostics.

The interdisciplinary collaboration fundamental to this research underscores an emergent trend in modern scientific investigation. Bridging neurology, analytical chemistry, computational biology, and clinical science, the study is a testament to how convergent expertise can unravel complex disease puzzles. Open data sharing and increasing use of artificial intelligence will likely accelerate similar breakthroughs, fostering rapid translation from bench to bedside.

In conclusion, the delineation of progression markers from the sebum volatilome by Walton-Doyle and colleagues represents a landmark advancement in Parkinson’s disease research. Through the elegant integration of metabolomic profiling and machine learning, this work not only pioneers a novel diagnostic modality but also enriches our understanding of disease mechanisms underpinning PD and iRBD. As validation efforts continue, the prospect of deploying non-invasive, cost-effective, and mechanistically informative biomarkers in clinical practice draws closer, offering hope for earlier diagnosis, better patient stratification, and ultimately, improved therapeutic outcomes in this devastating disease.

Subject of Research: Parkinson’s disease and isolated REM sleep behaviour disorder classification through sebum volatilome analysis.

Article Title: Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome.

Article References:
Walton-Doyle, C., Heim, B., Sinclair, E. et al. Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome. npj Parkinsons Dis. 11, 202 (2025). https://doi.org/10.1038/s41531-025-01026-8

Image Credits: AI Generated